Pharmaceutical cocrystals and a nitrate salt of voriconazole
Pharmaceutical cocrystals and a nitrate salt of voriconazole
| dc.contributor.author | Kumar, S. Sudalai | |
| dc.contributor.author | Thakuria, Ranjit | |
| dc.contributor.author | Nangia, Ashwini | |
| dc.date.accessioned | 2022-03-27T09:25:02Z | |
| dc.date.available | 2022-03-27T09:25:02Z | |
| dc.date.issued | 2014-06-14 | |
| dc.description.abstract | Voriconazole ((2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1- (1H-1,2,4-triazol-1-yl)butan-2-ol, VZL) is an antifungal drug with low aqueous solubility of 0.71 mg mL-1 and a BCS class II drug (Biopharmaceutics Classification System) of the azole family. We have prepared a nitrate salt and three cocrystals of VZL with p-hydroxybenzoic acid, p-aminobenzoic acid (both are GRAS compounds) and m-nitrobenzoic acid coformers to improve the physicochemical properties. All four multi-component crystals of voriconazole were obtained by solution crystallization as well as solid-state grinding and their structures were confirmed by X-ray diffraction, FT-IR, Raman and NMR spectroscopy, and thermal techniques. VZL-PHBA and VZL-PABA are isostructural based on XPac calculations and molecular packing arrangement. A notable result from a crystal engineering viewpoint is that the supramolecular synthon between the basic drug and the acidic coformer undergoes a switch based on the pK a of the acid. © 2014 the Partner Organisations 2014. | |
| dc.identifier.citation | CrystEngComm. v.16(22) | |
| dc.identifier.uri | 10.1039/c3ce42324g | |
| dc.identifier.uri | http://xlink.rsc.org/?DOI=C3CE42324G | |
| dc.identifier.uri | https://dspace.uohyd.ac.in/handle/1/12877 | |
| dc.title | Pharmaceutical cocrystals and a nitrate salt of voriconazole | |
| dc.type | Journal. Article | |
| dspace.entity.type |
Files
License bundle
1 - 1 of 1